Hepatitis C Virus (HCV) is a widely spread viral infection that affects millions of people worldwide. Liver cirrhosis and Hepatocellular Carcinoma have very strong link to liver viruses B and C. Sofosbuvir is a newly FDA approved drug (Dec. 2013) that acts against the spread of HCV. It is a Non-Structural 5B (NS5B) RNA dependent RNA polymerase (RdRp) Nucleoside Inhibitors (NI). Sofosbuvir is an anti-HCV drug among different compounds (e.g. IDX-184, R7128, etc.) that were under clinical trials for years. 

The lecture aims at providing a deep insight on the utilization of molecular modeling in conjunction with Quantitative Structure–Activity Relationship (QSAR) in studying the interaction between activated drugs and 12 amino acids constituting a 5 Å region surrounding the conserved active site motif GDD of HCV. These studies among many other studies on MERS CoV and Zika virus proteins would accelerate the rate of antiviral approval in pharmaceutical research and development.